Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

SNTI

Senti Biosciences Holdings Inc

Last Close
1.77
Nov 20 • 3:59 PM ET Dollar change-1.02 Percentage change(-36.56%)
Aftermarket Close
2.05
Aftermarket • 7:30 PM ET Dollar change+0.28 Percentage change(15.82%)
Nov 20, 6:31 PMNo clear catalyst identified for SNTI 37% drop after reverse-split trading
Index
-
Market Cap
4.60M
Enterprise Value
20.61M
Income
-43.02M
Sales
0.07M
Book/sh
-10.18
Cash/sh
2.14
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
39
IPO
May 26, 2021
P/E
-
Forward P/E
-
PEG
-
P/S
65.71
P/B
-
P/C
0.83
P/FCF
-
EV/EBITDA
-
EV/Sales
294.43
Quick Ratio
0.54
Current Ratio
0.54
Debt/Eq
-
LT Debt/Eq
-
Option/Short
No / Yes
EPS (ttm)
-47.72
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS past 3/5Y
50.33% 65.37%
Sales past 3/5Y
-82.75% -70.12%
EPS Y/Y TTM
56.67%
Sales Y/Y TTM
-
EPS Q/Q
46.17%
Sales Q/Q
-
Insider Own
0.00%
Insider Trans
-
Inst Own
54.17%
Inst Trans
0.53%
ROA
-106.17%
ROE
-466.46%
ROIC
-1555.46%
Gross Margin
-3816.22%
Oper. Margin
-70125.68%
Profit Margin
-58140.54%
SMA20
-64.57%
SMA50
-77.22%
SMA200
-91.85%
Trades
Shs Outstand
2.60M
Shs Float
2.60M
52W High
95.04 -98.14%
52W Low
2.50 -29.20%
Volatility
25.72% 18.22%
ATR (14)
0.85
RSI (14)
20.02
Beta
2.47
Rel Volume
0.39
Avg Volume
107.15K
Volume
41,634
Perf Week
-61.69%
Perf Month
-71.84%
Perf Quarter
-85.81%
Perf Half Y
-94.57%
Perf YTD
-94.84%
Perf Year
-97.04%
Perf 3Y
-98.53%
Perf 5Y
-99.95%
Perf 10Y
-
Prev Close
2.79
Price
1.77
Change %
-36.56%
Consensus
Strong Buy
Avg. Price Target
$495.00
Implied Upside
+27,866.1%
Analysts3incl. previous ratings
Rating Distribution2 Buy · 1 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Oct 14, 2025Initiated
HH.C. Wainwright
Buy$12+578.0%
Jun 06, 2025Initiated
LLaidlaw
Buy$5+182.5%
Oct 07, 2022Initiated
MS logoMMorgan Stanley
Equal-Weight$7.50+323.7%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
New Enterprise Associates 15, Former AffiliateNov 20 '26Proposed Sale2.79114,412319,209Nov 20 04:23 PM
Operates as a holding company whose subsidiary develops cell and gene therapies for cancer diseases
Ph.D.Dr. Timothy K. Lu M.D.
Ph.D.Dr. Kanya Rajangam M.D.
Scientific Co-FounderDr. James J. Collins Ph.D.
Chief Financial OfficerMr. Jay Cross
Senior Vice President of Technical OperationsMr. Faraz Siddiqui